Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
04/27 GILEAD SCIENCES : to Present Clinical and Preclinical Data on Nonalcoholic Steat..
04/27 GILEAD SCIENCES : Robin L. Washington Named "Financial Woman of the Year"
04/27 GILEAD SCIENCES : to Release First Quarter 2017 Financial Results on Tuesday, Ma..
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/26 GILEAD SCIENCES : Phase II study showed 99% HCV cure rates
04/21 GILEAD SCIENCES : Announces Scientific Presentations Demonstrating Efficacy of H..
04/21 GILEAD SCIENCES : Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Ste..
04/20 GILEAD SCIENCES : U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in..
04/20 GILEAD SCIENCES : Presents Data at the International Liver Congress™ 2017 ..
04/20 GILEAD SCIENCES : to Present Clinical and Preclinical Data on Nonalcoholic Steat..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/28 Is Bristol-Meyers Squibb A Good Long-Term Pick?
04/28 GILEAD SCIENCES : Low Expectations
04/27 BRISTOL-MYERS SQUIBB : Becoming An Increasingly Attractive Target
04/27 Gilead Sciences A Long Term Buy
04/27 Gilead M&A Scenerio
Advertisement
Financials ($)
Sales 2017 24 705 M
EBIT 2017 15 254 M
Net income 2017 10 151 M
Debt 2017 2 430 M
Yield 2017 3,11%
P/E ratio 2017 9,28
P/E ratio 2018 10,20
EV / Sales 2017 3,73x
EV / Sales 2018 4,09x
Capitalization 89 611 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,9 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-4.27%89 611
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
ACTELION LTD24.13%28 742
More Results